GLP-1 Market
LLY $1157.49 ▲ +1.3% NVO $37.53 ▼ -0.0% PFE $27.50 ▲ +0.3% VKTX $28.38 ▼ -3.1% KLRA $10.83 ▼ -0.1% GPCR $27.47 ▼ -0.4% RHHBY $52.55 ▲ +0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Sepiapterin

Company
Birmingham Women's and Children's NHS Foundation Trust
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 7, 2026

Find a Clinical Trial Near Me

See recruiting studies for Sepiapterin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06302348

    A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

    Not yet reported PTC Therapeutics 56 participants Est. completion 2031-02-28 10 sites Stand-alone
    Other conditions: Phenylketonuria
    View official trial listing →
  • Recruiting NCT NCT07728032

    Impact Of A Phe-Restricted Diet On Gut Health In Children With PKU

    Birmingham Women's and Children's NHS Foundation Trust 148 participants Est. completion 2026-12 1 site
    Other conditions: Phenylketonuria
    View official trial listing →
  • Completed NCT NCT03519711

    A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia

    Not yet reported, Not yet reported PTC Therapeutics 8 participants Est. completion 2020-10-02 4 sites
    Other conditions: BH4 Deficiency, Hyperphenylalaninemia
    View official trial listing →
  • Completed NCT NCT03712124

    A Study of CNSA-001 in Women With Diabetic Gastroparesis

    Not yet reported PTC Therapeutics 21 participants Est. completion 2019-10-08 6 sites
    Other conditions: Gastroparesis
    View official trial listing →
  • Completed NCT NCT05166161

    A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

    Not yet reported PTC Therapeutics 247 participants Est. completion 2026-07-21 46 sites
    Other conditions: Phenylketonuria
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Sepiapterin, Sephience

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.